Houston, TX, March 17, 2020 – Vivante Health, the leader in digital medicine for gut health and disease, proudly announced a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop digital predictive biomarkers for chronic diseases. The agreement was facilitated by Johnson & Johnson Innovation LLC.
The massive amount of information obtained through traditional electronic health data and, more recently, through digital health devices such as health apps is the driving force behind digital biomarkers. A growing field of study, digital biomarkers can explain, predict or influence health-related outcomes.
Since 2015, the Vivante team has been developing a comprehensive digital health platform for inflammatory conditions, with a primary focus on digestive health and disease. Vivante Health’s user-centric, data-rich platform captures real-time information and includes biometric testing, as well as microbiome analyses, to capture a holistic profile of individuals and match them with psychosocial, nutritional, and medication interventions to fill gaps in care and alter disease progression. With inflammation being at the root of digestive disorders such as Crohn’s disease and ulcerative colitis, digital biomarkers for inflammatory bowel disease will serve as a focus of the Vivante Health collaboration with Janssen.
The collaboration will expand the use of Vivante’s digital platform beyond treatment, toward prediction and early interception. Many seemingly healthy people are unknowingly incubating chronic inflammatory diseases. By using clinically relevant data to build a predictive disease model, those who are likely to develop disease or experience disease progression may be identified earlier. A digital medicine platform could then screen large populations, engage more deeply with those who are at increased risk, and potentially deliver meaningful solutions.
Dr. Simon C. Mathews MD, Vivante Health chief medical officer noted, “The ability to identify patients at risk for developing inflammatory disease and those that are more likely to experience disease progression is a critical step to potentially altering the natural history of disease for patients.” He added, “The collaboration with Janssen is an exciting opportunity since we share in their goals of intercepting disease and advancing precision medicine.”